October 2025, Vol 2, No 9
October is a month of reflection and recognition across the federal health landscape. As we observe American Pharmacists Month and Breast Cancer Awareness Month and look ahead to Veterans Day in November, this issue of ImPACT highlights reports that honor the resilience of our nation’s veterans and the professionals who serve them—through science, care, and innovation. Read More ›
By Tyler Smith
About a decade ago, Lisa Brenner, PhD, helped conduct interviews at Fort Carson in Colorado Springs, CO, with 103 soldiers who had returned from the conflicts in Iraq and Afghanistan. She and her colleagues wanted to understand the physical and emotional effects of the veterans’ deployments. Their responses painted a complicated picture. Read More ›
By Emily Bell
Navy Veteran Matthew Roach rang the celebration bell at the Lubbock VA Clinic on July 8, 2025, signifying his official triumph over terminal stage IV metastatic prostate cancer 1 year after being diagnosed. Read More ›
As the sole psychiatric pharmacist on faculty at the University of Houston College of Pharmacy (UHCOP), Austin De La Cruz, PharmD, BCPP, wears many hats. Or, perhaps one could say many “coats.” He is a clinical associate professor in UHCOP’s Department of Pharmacy Practice and Translational Research and a clinical pharmacy specialist–psychiatry at Michael E. DeBakey Veterans Affairs (VA) Medical Center. Read More ›
It’s Breast Cancer Awareness Month, and officials with Veterans Affairs (VA) are encouraging patients to be screened and perform regular self-checks. Read More ›
In June, the Department of Veterans Affairs (VA) announced the availability of $42 million in grants to eligible organizations to assist homeless veterans and those at risk of homelessness with various legal services, and those operations will begin to be funded this month, on October 1, 2025, and continuing until September 30, 2027. Read More ›
The Department of Veterans Affairs (VA) recently announced that eligible veterans can now submit and track “mileage-only” travel claims directly from a smartphone or mobile device via the VA Health and Benefits mobile app. Read More ›
Officials with the FDA have granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for adults with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. Read More ›
On August 6, 2025, officials with the FDA granted accelerated approval to dordaviprone (Modeyso), a protease activator, for adult and pediatric patients aged ≥1 year with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy. Read More ›